DBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Saturday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of DBV Technologies in a report on Wednesday, February 21st.

DBV Technologies Stock Up 3.1 %

Shares of DBV Technologies stock opened at $0.68 on Friday. The business has a 50 day moving average of $0.79 and a 200 day moving average of $0.89. DBV Technologies has a 52 week low of $0.65 and a 52 week high of $2.37. The company has a market cap of $131.48 million, a PE ratio of -1.75 and a beta of 0.75.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.10. The business had revenue of $8.88 million during the quarter, compared to analyst estimates of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same period in the prior year, the business earned ($0.23) EPS. On average, research analysts anticipate that DBV Technologies will post -0.88 earnings per share for the current year.

Institutional Trading of DBV Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of DBVT. Goldman Sachs Group Inc. boosted its stake in DBV Technologies by 225.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 46,805 shares of the company’s stock worth $45,000 after acquiring an additional 32,405 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of DBV Technologies by 91.1% in the 4th quarter. Citadel Advisors LLC now owns 163,346 shares of the company’s stock worth $156,000 after purchasing an additional 77,861 shares in the last quarter. Cowen AND Company LLC purchased a new stake in shares of DBV Technologies in the 4th quarter worth approximately $49,000. Optiver Holding B.V. grew its stake in shares of DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares during the last quarter. Finally, Landscape Capital Management L.L.C. bought a new position in DBV Technologies during the 3rd quarter valued at approximately $94,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.